Vivo Bio Tech profitability ratios

Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024
Returns
11.4%4.6%
5.5%1.9%
11.2%12.2%
7.6%5.9%
Margins
44.6%47.0%
25.2%26.3%
−0.7%—
19.5%9.0%
16.2%5.6%
−22.4%17.6%
Additional
16.6%37.8%
11.4%4.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health
₹ CroreMcap ₹21.4 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Returns
Return on Common Equity4.6411.42
Return on Assets1.875.48
Return on Capital Employed12.1611.20
Return on Invested Capital5.927.63
Margins
EBITDA Margin46.9844.56
Operating Margin26.2825.24
Incremental Operating Margin—-0.74
Pretax Margin9.0319.46
Net Income Margin5.6216.22
FCF Margin17.56-22.37
Additional
Effective Tax Rate37.7916.63
Sustainable Growth Rate4.6411.42
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.